Enovis (ENOV)

The company operates through two main reporting segments: Prevention & Recovery and Reconstructive. Prevention & Recovery is the larger contributor to revenue and includes products used by orthopaedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers, and other healthcare providers. These products are designed to treat and manage conditions caused by degenerative disease, deformity, sports injury, trauma, and overuse. The segment includes bracing, supports, rehabilitation technologies, and related solutions that help patients regain mobility or reduce pain.

The Reconstructive segment focuses on implants and surgical technologies used in joint replacement and other orthopaedic procedures. This gives Enovis exposure to demand from ageing populations, rising rates of osteoarthritis, and the continued adoption of procedures that aim to restore function and improve quality of life.

Enovis serves hospitals, clinics, rehabilitation centres, and healthcare professionals through a global commercial footprint. Its competitive position depends on product innovation, surgeon and clinician relationships, distribution strength, and the ability to demonstrate clinical and economic value. For investors, Enovis represents a specialised medtech business tied to long-term demand for musculoskeletal care, elective orthopaedic procedures, and rehabilitation solutions.